Millions of people living with osteoarthritis are told the same story: manage your symptoms, protect your joints, and prepare for the possibility of surgery. But a growing number of patients and physicians are asking whether regenerative medicine can rewrite that narrative. Stem cell injections for osteoarthritis have emerged as one of the most talked-about developments in joint health over the past decade, promising to do what conventional treatments cannot, which is potentially slow or even reverse the underlying damage driving the disease.
The excitement is understandable. The science, however, is more complicated. Before committing to a treatment that can carry significant costs and variable outcomes, it is worth examining what the clinical evidence actually supports. In this analysis, we break down how stem cell therapies work within the context of osteoarthritis, what current research reveals about their effectiveness and safety, and where the genuine gaps in our knowledge still lie. Whether you are a patient weighing your options or a clinician staying current with emerging therapies, this evidence-based review will give you a clearer, more grounded picture of where this promising field truly stands.
What Is Osteoarthritis and Why Is Cartilage So Hard to Treat?
Osteoarthritis (OA) is a progressive degenerative joint disease characterised by the breakdown of articular cartilage, the smooth, protective tissue that lines the ends of bones within a joint. As this cartilage deteriorates, bone surfaces begin to make contact with one another, triggering pain, stiffness, swelling, and a gradual but significant loss of joint function. OA is not simply a consequence of ageing; it can also develop following acute injury or repetitive mechanical stress, and once established, it follows a progressive course that conventional treatments can only partially address.
The scale of the problem in the UK is considerable. According to Versus Arthritis, osteoarthritis is the most common form of arthritis in the UK, affecting an estimated 8.75 million people, with the knee, hip, and hand joints most frequently involved. For patients in Wales and across the broader UK, this represents an enormous burden on both quality of life and healthcare resources, and it underscores the urgent need for more effective treatment options beyond pain relief alone.
The fundamental challenge in treating OA lies in the biology of cartilage itself. Unlike most tissues in the body, articular cartilage has almost no blood supply and displays very low metabolic activity. It relies on diffusion through joint fluid for nutrition rather than a dedicated vascular network. This means that when cartilage is significantly damaged, the repair signals and cellular resources the body normally deploys simply cannot reach it effectively. As research published via the NIH confirms, while minor injuries may be partially addressed by resident chondrocytes, there is very little capacity for a severely compromised joint to regenerate without therapeutic intervention.
This biological limitation is precisely why regenerative medicine has attracted such serious clinical and scientific attention. If the body cannot repair cartilage on its own, the logical clinical response is to introduce therapies capable of stimulating or substituting that process. Knee OA has become the primary focus of stem cell research to date, partly because of its high prevalence and partly because the consequences of joint failure in younger, active patients, including the considerable risks and revision rates associated with total knee replacement, make effective biological alternatives a genuine clinical priority.
What Are Stem Cell Injections and How Are They Thought to Work?
At the centre of this treatment category are mesenchymal stem cells, commonly referred to as MSCs. In straightforward terms, these are undifferentiated cells, meaning they have not yet committed to a specific biological role. They carry the theoretical capacity to develop into several tissue types relevant to joint health, including cartilage, bone, muscle, and vascular tissue. It is precisely this biological flexibility that has made them the subject of significant research interest in osteoarthritis management. While the term “stem cell injection” has become widely used in patient-facing content, it is worth noting that researchers increasingly use the term “mesenchymal stromal cells” interchangeably, reflecting ongoing scientific discussion about their precise classification and behaviour once introduced into the body.
How MSCs Are Proposed to Work
Two distinct mechanisms have been put forward to explain any potential benefit, and they are not mutually exclusive.
The first is direct regenerative potential. The theory here is that MSCs, once injected into a damaged joint, may differentiate into chondrocytes, the specialised cells responsible for producing and maintaining cartilage. If this occurred meaningfully in a clinical setting, it could represent a genuine repair mechanism for tissue that, as discussed previously, has very limited capacity for self-repair. However, the degree to which injected MSCs actually undergo this differentiation process within a living joint remains under active investigation, and it should be understood as a theoretical rather than confirmed mechanism.
The second proposed mechanism is anti-inflammatory and immunomodulatory signalling. This is currently considered by many researchers to be the more likely driver of observed short-term benefit. MSCs are thought to release bioactive molecules, including cytokines, growth factors, and extracellular vesicles, that dampen the inflammatory environment within the joint, reduce pain signalling, and potentially slow the progression of cartilage degradation. This paracrine signalling effect does not require the cells to permanently integrate into joint tissue, which may help explain why some patients report symptomatic improvement even when structural regeneration cannot be confirmed on imaging.
The Three Main Cell Sources
All three MSC sources investigated in formal clinical trials carry different harvesting procedures, processing requirements, and theoretical profiles, and understanding these differences is important when evaluating treatment options.
Bone marrow aspirate concentrate (BMAC) is drawn from the patient’s own bone marrow, most commonly from the iliac crest of the hip, then concentrated using a centrifuge before injection. This is an autologous approach, meaning the patient serves as their own donor, which minimises immune rejection risk. The procedure does require a bone marrow harvest on the same or a prior visit, and the true MSC yield within the resulting concentrate can vary between patients.
Stromal vascular fraction (SVF) is derived from the patient’s own adipose, or fat, tissue, typically harvested via a lipoaspiration procedure. Fat tissue is relatively abundant and accessible, which makes it an attractive autologous source. However, processing the harvested material to isolate the cell-rich fraction adds procedural steps and associated complexity.
Umbilical cord-derived MSCs represent the allogeneic option, sourced from donated cord tissue (specifically Wharton’s Jelly) following consented births. Unlike autologous approaches, these donor-derived cells can be prepared in advance, batch-tested, and stored for use without requiring the patient to undergo a harvest procedure. MSCs are considered “immune-privileged” due to low expression of markers that typically trigger rejection responses, making allogeneic use theoretically feasible. That said, the immune response question remains an active area of investigation, as confirmed by a 2024 clinical study protocol published in Trials specifically designed to examine the mechanisms of allogeneic cord-derived MSCs in knee OA.
The autologous versus allogeneic distinction matters practically as well as biologically. Autologous procedures require additional clinical steps to harvest and process the patient’s own cells, which affects procedural complexity, visit requirements, and the fact that cell quality may be influenced by the patient’s age or health status. Allogeneic products remove this burden but introduce different regulatory and scientific considerations. A 2026 systematic review and meta-analysis examining MSC-based therapy across multiple clinical trials reflects how actively this comparative question is being pursued in the current literature. Each source carries its own profile of potential advantages, and no single approach has yet demonstrated clear clinical superiority over the others.
What Does the Current Clinical Evidence Actually Show?
The most important question any clinician or patient can ask about stem cell injections for osteoarthritis is a straightforward one: what does the best available evidence actually demonstrate? Setting aside theoretical mechanisms and early-stage optimism, the honest answer requires engaging with the trials that have been designed rigorously enough to give us reliable answers.
The MILES Study: The Benchmark Trial
The landmark reference point in this field is the MILES study (Multicenter Trial of Stem Cell Therapy for Osteoarthritis), published in Nature in 2024. This is, to date, the largest and most methodologically rigorous randomised controlled trial conducted in this treatment category. The trial enrolled 480 diverse participants aged 40 to 70, all with a confirmed unilateral knee OA diagnosis, across four clinical sites. Critically, it compared three distinct MSC preparations, sourced from bone marrow concentrate, adipose-derived tissue, and umbilical cord tissue, directly against corticosteroid injection as the active comparator.
The findings were unambiguous. At 12-month follow-up, none of the three MSC conditions demonstrated statistically significant superiority over corticosteroid injection for either pain reduction or functional improvement. MRI measurements of cartilage thickness showed no meaningful differences between groups. Patients across all arms, including those who received the corticosteroid control, experienced broadly comparable modest improvements.
Interpreting Equivalence Honestly
It is important to read these results carefully rather than reactively. Equivalence to corticosteroid injection is not, in itself, a clinical failure. Patients treated with MSC injections did improve, and that improvement is real. What the MILES trial does challenge, however, is the “game changer” framing that has surrounded stem cell therapy in some clinical marketing and in earlier research literature. Several prior studies, many of which relied on survey-based methodology or smaller, less controlled designs, suggested substantially stronger benefit than the MILES trial was ultimately able to confirm. When subjected to a rigorous, multi-site, randomised design with an active comparator rather than a passive placebo, those earlier signals did not hold. This is not unusual in the evolution of any treatment category, but it does mean that claims of transformative superiority are not currently supported by the highest-quality evidence available.
The Cochrane Collaboration’s systematic review of stem cell injections for knee OA reinforces this picture. Across 25 randomised trials involving 1,341 patients, stem cell injections produced a mean pain improvement of approximately 1.2 points on a 0 to 10 scale and a function improvement of 14.2 points on a 0 to 100 scale, measured against placebo at up to six months. Cochrane graded the overall certainty of evidence as low, citing inconsistent study designs, varied cell processing methods, and a high risk of bias across included trials. Cartilage regeneration was not confirmed.
The SCUlpTOR Trial and the Structural Question
One of the most intellectually significant trials in this space is the SCUlpTOR trial, published in BMJ Open in 2021. Its importance lies in its design: rather than measuring pain scores alone, the SCUlpTOR trial was specifically constructed to examine structural cartilage improvement as a primary endpoint in tibiofemoral knee OA. This distinction matters considerably. If the core biological argument for MSC therapy is genuine tissue regeneration, then pain reduction, while meaningful, is an incomplete test of that proposition. Demonstrating actual structural change in cartilage via imaging would provide fundamentally stronger evidence for disease-modifying potential. The SCUlpTOR trial represents the methodological standard the field must meet if it is to substantiate its regenerative claims with confidence.
Next-Generation Research and the Road Ahead
The field is not static. Researchers at the Wake Forest Institute for Regenerative Medicine (WFIRM) are actively developing next-generation injectable cell therapies specifically engineered to target OA resolution, going beyond current first-generation MSC formulations. This work is scientifically significant because it acknowledges a likely truth: the MSC preparations in use today may not be the optimised or final iteration of this treatment category. The underlying biological rationale, that appropriately prepared cells can shift a joint from a pro-inflammatory to a pro-reparative state, remains scientifically credible and continues to drive active investigation.
The honest overall picture, viewed from a clinician’s perspective, is this: stem cell injections for osteoarthritis rest on a genuine biological rationale, produce real benefit for patients in terms of pain and function, and continue to attract serious scientific investment. However, the evidence base is still maturing. The highest-quality trials conducted to date have not demonstrated clear structural cartilage regeneration or consistent superiority over established injection therapies. For patients and clinicians alike, understanding that distinction is the foundation of a properly informed treatment decision.
How Do Stem Cell Injections Compare to Other Injection Therapies?
Understanding how stem cell injections fit within the broader injection therapy landscape requires a shift in perspective. This is not a straightforward hierarchy where one treatment wins and others lose. Instead, different injection therapies work through distinct biological mechanisms, carry different levels of clinical evidence, and are appropriate for different patients at different stages of osteoarthritis progression. Thinking of these options as a treatment pathway, rather than a competitive ranking, leads to better clinical decisions and more realistic patient expectations.
Corticosteroid (Steroid) Injections
Corticosteroid injections have long represented the standard benchmark for managing OA symptoms in clinical practice. Their appeal is well established: they deliver fast-acting anti-inflammatory relief, are widely available, and carry decades of clinical data supporting their short-term effectiveness. For patients in acute flare or those who need rapid symptom control before a planned intervention, they remain a clinically appropriate choice. However, the picture surrounding long-term and repeated steroid use has grown more complicated. Multiple studies now indicate that repeated corticosteroid administration is associated with cartilage degradation over time, which is a significant concern in a condition already defined by progressive cartilage loss. A 2024 network meta-analysis published in Arthroscopy found that PRP, BMAC, and hyaluronic acid all outperformed corticosteroids in pain and function scores at a minimum six-month follow-up, reflecting a meaningful shift in how the field is evaluating these options.
Platelet-Rich Plasma (PRP) Injections
PRP sits closest to stem cell therapy within the regenerative medicine conversation. It is derived from the patient’s own blood, concentrated to produce a growth-factor-rich preparation that harnesses the body’s own healing mechanisms to reduce inflammation and support tissue health. The evidence base for PRP in knee OA is the most robust of any orthobiologic treatment currently available, with PRP consistently outperforming placebo, corticosteroids, and hyaluronic acid across multiple randomised controlled trials. For patients considering regenerative options, PRP represents a well-evidenced, lower-complexity starting point. It is already an established part of the injection therapy portfolio at Pro Sports Medicine in Cardiff, where it is delivered under ultrasound guidance by experienced Sports Medicine clinicians.
Hyaluronic Acid and Arthrosamid
Hyaluronic acid (viscosupplementation) works by replenishing the natural synovial joint fluid, restoring lubrication and mechanical cushioning within the joint space. It carries a long clinical track record and a good tolerability profile, making it a well-suited option for patients who are not candidates for biologic therapies or who present with milder OA. The same 2024 Arthroscopy meta-analysis confirmed its advantage over corticosteroids at six months. Hyaluronic acid is also available at Pro Sports Medicine as part of a structured injection pathway. Arthrosamid, a non-biodegradable polyacrylamide hydrogel, represents a newer and distinct intra-articular option. Rather than working biologically, it functions by cushioning the joint environment itself, and early clinical data suggests a durable effect profile. Arthrosamid is also part of the Pro Sports Medicine injection portfolio.
Where Stem Cell Injections Fit
Stem cell injections, most commonly delivered as bone marrow aspirate concentrate (BMAC) containing mesenchymal stem cells, occupy an aspirational position in this landscape. The theoretical rationale is compelling, and early-phase research has shown promising signals, including a 2024 systematic review finding MSC injections more effective than hyaluronic acid with comparable safety profiles. However, direct comparisons with PRP have not consistently demonstrated that stem cells offer superior outcomes, which matters considerably when weighing a treatment that involves greater procedural complexity, higher cost, and the need for either bone marrow or adipose tissue harvest. In the UK, stem cell injection availability remains limited compared to established orthobiologics, and the evidence base, while growing, is still catching up to the treatment’s theoretical promise. For a detailed comparison of injection options for knee OA, the clinical picture continues to evolve rapidly.
Are Stem Cell Injections Safe? Understanding the Risk Profile
Safety is a central concern for any patient exploring regenerative treatments, and it is important to address it with clarity rather than generalisation. The risk profile of stem cell injections varies meaningfully depending on the cell source, the processing method, and the clinical setting in which treatment is delivered.
Autologous Procedures: Lower Immune Risk With Procedural Considerations
Autologous approaches, including BMAC and adipose-derived SVF, use the patient’s own biological material. This theoretically reduces the risk of immune rejection, since the body is less likely to mount an adverse response to its own cells. However, the harvesting procedure itself introduces a separate category of risk. Extracting bone marrow from the iliac crest or harvesting adipose tissue from subcutaneous fat requires an invasive procedure at the donor site, and recognised complications include localised infection, haematoma formation, and post-procedural discomfort. A 2024 systematic review published in HSS Journal specifically examined complications of stem cell-based injections for knee OA and noted that adverse event rates across the existing literature remain poorly characterised, underscoring the need for cautious interpretation and expert clinical oversight.
Allogeneic Therapy and Regulatory Oversight
Allogeneic MSC therapy, most commonly derived from umbilical cord tissue, introduces additional considerations. Donor cells undergo screening and processing before use, but questions around immune response and long-term safety remain active areas of investigation. In the UK, allogeneic cell-based products would typically be classified as Advanced Therapy Medicinal Products (ATMPs) under the regulatory framework overseen by the MHRA. As of the time of writing, no stem cell therapy for osteoarthritis holds a standard marketing authorisation in the UK for routine clinical use. Patients should verify the regulatory basis under which any treatment is being offered, whether within an approved clinical trial or under another specific pathway, by consulting the MHRA directly before proceeding.
The Injection Itself Versus the Cell Product
A distinction worth making clearly: when stem cell therapy is delivered via ultrasound-guided intra-articular injection by a trained clinician, the joint injection itself is a well-established, low-risk procedure used routinely across musculoskeletal medicine. The additional risk associated with stem cell therapy relates primarily to the biological product being injected, specifically how the cells were sourced, processed, and stored, rather than to the injection technique itself.
Patients should also exercise caution when considering overseas clinics that market stem cell treatments outside the scope of UK or EU regulatory standards. Treatments offered in unregulated or poorly regulated environments carry risks that are difficult to quantify and harder to manage if complications arise. Before pursuing any cell-based therapy, seeking assessment from a qualified sports medicine physician or orthopaedic consultant is strongly advisable.
Who Is a Good Candidate for Stem Cell Therapy, and Who Is Not?
The patient profile most consistently investigated in stem cell OA research follows a recognisable pattern. Clinical trials, including the MILES study, have focused on adults broadly between the ages of 40 and 70, with a confirmed OA diagnosis, evidence of moderate joint degeneration, and a history of inadequate response to conventional management. In practical terms, this typically means a patient who has worked through a structured course of physiotherapy, trialled anti-inflammatory medication, and possibly received corticosteroid or hyaluronic acid injections, yet continues to experience significant pain and functional limitation. This is the patient who is neither in the earliest stage of disease nor facing a severely deteriorated joint, and who is actively looking to explore regenerative options before committing to surgical intervention.
When Stem Cell Therapy May Not Be Appropriate
Not every OA patient is a suitable candidate, and understanding the contraindications is just as clinically important as recognising who might benefit. Active joint infection is an absolute contraindication across all injectable therapies. Active or recent malignancy is a key disqualifying factor during candidate screening, given the theoretical risk of stimulating cell proliferation in an oncological context. Patients on immunosuppressive medication require careful evaluation, as the regenerative environment depends on intact cellular activity. Bleeding disorders are a particular consideration for bone marrow aspirate concentrate (BMAC) procedures, which involve an aspiration step and carry specific procedural risks in this group. Further detail on candidate screening factors for stem cell therapy reinforces that formal clinical assessment, not patient self-selection, is the appropriate route to eligibility.
Why OA Grade and Imaging Are Central to the Decision
Disease stage is arguably the most critical variable in determining whether a regenerative approach is warranted. Patients with early-to-moderate OA, broadly corresponding to Kellgren-Lawrence Grades I to III, retain sufficient cartilage tissue to provide a structural target for regenerative mechanisms. In contrast, a patient with Grade IV, bone-on-bone joint space narrowing, has limited remaining tissue for any regenerative process to act upon, and expectations must be calibrated accordingly. A detailed overview of outcomes by OA grade for knee stem cell therapy illustrates why the staging conversation is not optional but foundational to treatment planning. MRI and diagnostic ultrasound are the primary imaging modalities used to characterise joint space, assess cartilage integrity, and evaluate the synovial environment prior to any regenerative injection.
At Pro Sports Medicine, this level of assessment is embedded within the clinic’s standard of care. The multidisciplinary team, which includes sports medicine doctors, orthopaedic consultants, and a consultant radiologist, is specifically positioned to carry out the clinical examination and imaging review required before any regenerative therapy is considered. This integrated capability means that imaging interpretation, clinical context, and treatment planning are aligned within a single pathway, rather than fragmented across disconnected referrals. Matching the right treatment to the right patient at the right stage of disease is not incidental to good regenerative medicine practice; it is the foundation of it.
Stem Cell Injections for OA: Availability and Cost in the UK
Stem cell injections for osteoarthritis are not currently commissioned as a standard NHS treatment in England or Wales. NICE has not approved these therapies for routine clinical use, and patients seeking this intervention will need to access it through a specialist private clinic. This is an important distinction to understand before beginning any search for treatment options.
One of the more significant challenges facing UK patients is the sheer volume of online content that originates from US clinics, medical tourism facilitators, and international treatment platforms. Destinations including Mexico, Thailand, Turkey, and Colombia are heavily marketed online, and platforms report handling hundreds of thousands of treatment requests across international networks. This creates a misleading impression of widespread accessibility that does not reflect the reality of the UK private market, where specialist availability is considerably more limited.
On cost, transparency is difficult to establish with precision. UK private pricing for stem cell injections is broadly estimated in the range of £3,000 to £10,000 or more per treatment episode, though this varies considerably depending on several factors. Autologous procedures, which require harvesting cells from your own bone marrow or adipose tissue, involve significantly greater procedural complexity than allogeneic injections using donor-derived cells. The number of joints being treated and the clinical setting will also influence the final cost.
Medical tourism carries specific and well-documented risks in this area. A peer-reviewed review of international stem cell tourism notes that many overseas clinics offering stem cell therapies are based in countries where regulatory oversight, cell processing standards, and post-treatment follow-up may not meet the standards required in the UK. Patients who experience complications following treatment abroad often face serious difficulties in accessing appropriate follow-up care or pursuing any form of redress.
Before engaging with any clinic, domestic or international, patients should ask a specific set of questions: what is the cell source and is it autologous or allogeneic; what regulatory framework governs the treatment; what peer-reviewed evidence supports the specific protocol being offered for osteoarthritis; and what follow-up care is included. Stem cell tourism research consistently highlights that patients who seek treatments outside properly regulated frameworks place themselves at heightened risk. At Pro Sports Medicine, our team of sports medicine doctors and orthopaedic consultants can help you evaluate whether any proposed intervention is clinically appropriate and evidentially supported before you commit to a course of treatment.
Our Approach to Regenerative Medicine at Pro Sports Medicine
At Pro Sports Medicine in Cardiff, we want to be transparent: stem cell injections are not currently offered as part of our clinical services. This article is intended as an educational resource, reflecting our commitment to keeping patients and referring clinicians informed as the evidence base in this area continues to evolve. We monitor emerging research closely, and our position is simple: when the clinical evidence is sufficiently robust and regulatory pathways are clear, we will evaluate whether stem cell therapies have a place within our portfolio. Until that point, we will not follow market trends ahead of the science.
What We Currently Offer
Our regenerative and injection therapy portfolio reflects treatments with a well-established clinical rationale. We currently offer platelet-rich plasma (PRP), hyaluronic acid viscosupplementation, Arthrosamid, and corticosteroid injections, each deployed appropriately depending on the patient’s diagnosis, disease severity, and goals. Where clinically indicated, these injections are delivered under ultrasound guidance to maximise precision and therapeutic accuracy. Importantly, these therapies sit within a broader multidisciplinary framework rather than functioning as standalone interventions.
An Evidence-Led Philosophy Since 2008
Founded in 2008 with the mission of bringing elite-standard sports medicine to every patient, Pro Sports Medicine has always prioritised clinical rigour over commercial pressure. Our approach to osteoarthritis management reflects this directly. Rather than recommending treatments based on marketing appeal, we build every treatment plan around the available evidence, your individual imaging findings, and your functional objectives.
Your Pathway at Pro Sports Medicine
A patient presenting with OA-related joint pain would typically begin with a sports medicine or orthopaedic consultation, followed by relevant imaging, whether diagnostic ultrasound or MRI, to establish an accurate picture of the joint. From there, a personalised treatment plan is developed, integrating the most appropriate injection therapy alongside physiotherapy for rehabilitation and load management, with ongoing monitoring throughout recovery. Our multidisciplinary team, comprising sports medicine doctors, physiotherapists, orthopaedic consultants, and a consultant radiologist, ensures that every decision is informed by specialist expertise across the full clinical picture.
The Bottom Line on Stem Cell Injections for Osteoarthritis
Stem cell injections for osteoarthritis carry genuine biological logic, have produced real clinical benefit in trials, and represent one of the more scientifically grounded approaches in regenerative medicine. The honest summary, however, is that the most rigorous evidence available to date, most notably the landmark MILES trial published in Nature Medicine, shows equivalence with corticosteroid injection rather than superiority. That finding does not dismiss the value of regenerative approaches; it simply means the conversation is still developing, and clinical decisions should reflect that reality.
The evidence base is actively evolving. Trials such as SCUlpTOR are beginning to examine whether stem cell therapy can achieve structural cartilage improvement, not just symptom relief. If that evidence matures positively, it could meaningfully reframe how these treatments are positioned. Until then, cautious optimism grounded in current data is the appropriate clinical stance.
What matters most for anyone managing osteoarthritis is avoiding treatment decisions driven by marketing rather than medicine. Overseas stem cell clinics and high-cost private packages are widely advertised, often with claims that outpace peer-reviewed evidence. A thorough assessment with a qualified sports medicine or orthopaedic specialist remains the most reliable starting point.
If you are considering injection therapy for osteoarthritis and want honest, evidence-based guidance on which option suits your situation, the team at Pro Sports Medicine in Cardiff is available to help. We offer comprehensive clinical assessment and a full range of injection therapies, and we will always recommend what the evidence supports for your individual case.
Conclusion
Stem cell therapy for osteoarthritis sits at a genuinely promising but still-evolving crossroads. The key takeaways are clear: early research shows meaningful potential for reducing pain and improving joint function, the safety profile appears generally favorable, and yet large-scale standardized clinical trials remain limited. Most importantly, no regulatory body has approved these treatments as a proven standard of care.
That does not mean the door is closed. It means informed decision-making has never mattered more.
If you are living with osteoarthritis, speak openly with a qualified specialist about your candidacy, the specific cell source being used, and realistic outcome expectations. Ask for peer-reviewed evidence, not just patient testimonials.
The science of regenerative medicine is advancing rapidly. Staying informed, asking hard questions, and partnering with evidence-based providers puts you in the strongest possible position to benefit when the research finally catches up to the promise.
